New Research Reveals Healthcare Leaders Who Unite Financial and Clinical Data Recover Millions in Previously Missed Revenue

Waystar’s numbers look strong, but some big claims lack hard proof or full transparency.

What the company is saying

Waystar is positioning itself as an indispensable technology partner for healthcare providers seeking to modernize and optimize their revenue cycle operations. The company’s core narrative is that its AI-powered, integrated platform directly addresses the most pressing pain points in healthcare payments—namely, fragmented systems, manual processes, and the inability to keep up with payer policy changes. Waystar claims that organizations fully leveraging its platform see dramatic improvements: an 87% increase in clinical documentation integrity (CDI) program impact, $2.17 million in incremental reimbursement per 10,000 discharges, and an 8.4-point boost in Patient Safety Indicator Composite (PSI-90) scores. The announcement repeatedly emphasizes realized, data-backed operational and financial gains, such as a 13% increase in observation-to-inpatient conversion rates and a reduction in medical-necessity denial rates to below 2%. However, it buries or omits any discussion of costs, profitability, competitive threats, or the challenges of implementing such a platform at scale. The tone is confident and assertive, with management projecting a sense of inevitability about the need for unified, AI-driven solutions. Matt Hawkins, identified as Chief Executive Officer, is the only notable individual with a clear institutional role; his involvement signals executive-level commitment but does not, by itself, guarantee broader market adoption or financial success. The communication style is data-heavy but selectively so, focusing on positive client outcomes while sidestepping broader financial disclosures. This narrative fits into a classic investor relations strategy: highlight operational wins and market reach to reinforce the company’s leadership position, while minimizing attention to risks or gaps. Compared to prior communications (where available), there is no evidence of a major shift in messaging, but the current announcement leans heavily on realized impact metrics to bolster credibility.

What the data suggests

The disclosed numbers paint a picture of significant operational improvements for organizations using Waystar’s platform. Specifically, clients report an 87% increase in CDI program impact and $2.17 million in incremental reimbursement per 10,000 discharges, which are substantial gains in the context of healthcare revenue cycles. The data also shows a 13% increase in observation-to-inpatient conversion rates and a reduction in medical-necessity denial rates to less than 2%, both of which directly translate to improved revenue capture and reduced financial risk. Additionally, organizations utilizing automated charge, coding, and documentation reviews report up to $3 million in incremental revenue per 10,000 admissions and a 90% increase in net rebilled dollars for coding anomalies compared with 2024 results, indicating a strong year-over-year improvement. The financial trajectory, at least for Waystar’s clients, appears to be improving, with most metrics showing positive movement over the prior period. However, the data is incomplete from an investor’s perspective: there is no disclosure of company-wide revenue, profitability, cost structure, or customer churn, making it impossible to assess overall financial health or sustainability. Some headline claims—such as market coverage percentages and client quality (e.g., serving 16 of 20 top hospitals)—are not directly substantiated with verifiable data. An independent analyst would likely conclude that while the operational impact for users is real and material, the absence of traditional financial disclosures and the selective nature of the data limit the ability to draw firm conclusions about Waystar’s own financial trajectory or competitive moat.

Analysis

The announcement is generally positive in tone and provides a range of realised, data-backed operational and financial metrics tied to Waystar's platform usage. Most claims are supported by survey data or measured client outcomes, such as percentage improvements and incremental revenue figures, indicating actual impact rather than mere projections. However, some language inflates the narrative, such as references to 'unanimous interest' and broad market coverage percentages, which are not directly substantiated by the disclosed data. The forward-looking statements are limited and mostly aspirational, focusing on the company's vision and recommended strategies rather than unsubstantiated future financial outcomes. There is no mention of large capital outlays or delayed benefit realisation, and the benefits described are either already realised or immediately achievable for current users. The gap between narrative and evidence is moderate, with most hype stemming from unquantified claims of market leadership and platform necessity.

Risk flags

• ●Selective disclosure risk: The announcement provides detailed operational metrics but omits key financial data such as revenue, profitability, and cost structure. This lack of transparency makes it difficult for investors to assess the company’s overall financial health or sustainability.
• ●Unsupported market leadership claims: Assertions about market coverage (e.g., serving 60% of U.S. patients or 16 of 20 top hospitals) are not backed by direct evidence or third-party validation. Investors should be wary of taking these claims at face value without supporting data.
• ●Forward-looking narrative risk: While most claims are realized, the company’s vision for a unified, AI-powered platform as a market necessity is inherently forward-looking and assumes continued adoption and integration, which may not materialize as projected.
• ●Operational execution risk: Achieving the reported benefits requires full and effective implementation of Waystar’s platform, which may be challenging for some organizations due to integration complexity, staff training, or resistance to change.
• ●Competitive landscape risk: The announcement does not address the presence or strategies of competitors, leaving open the possibility that similar or superior solutions exist, which could erode Waystar’s market share or pricing power.
• ●Data comparability risk: Some metrics are presented in isolation or as improvements over prior periods without sufficient context, making it hard to assess whether these gains are sustainable or representative across the client base.
• ●Client concentration and churn risk: There is no disclosure of customer retention rates or revenue concentration, which could mask underlying volatility if a few large clients account for a disproportionate share of business.
• ●Notable individual caveat: While CEO Matt Hawkins’ involvement signals executive commitment, it does not guarantee broader institutional buy-in or future financial performance; investors should not conflate leadership enthusiasm with market inevitability.

Bottom line

For investors, this announcement demonstrates that Waystar’s platform is delivering measurable operational and financial benefits to its clients, with specific, realized improvements in revenue capture, denial reduction, and clinical documentation. However, the company’s narrative is more credible on the operational impact side than on claims of market dominance or client quality, as the latter are not directly substantiated with hard evidence. The absence of traditional financial disclosures—such as revenue, profit margins, or cost structure—means that investors cannot fully assess the company’s financial health, scalability, or risk profile. CEO Matt Hawkins’ leadership is a positive signal of executive focus, but it does not guarantee future growth or competitive advantage. To materially change this assessment, Waystar would need to provide transparent, third-party-verified data on market share, client retention, and comprehensive financial statements. In the next reporting period, investors should watch for disclosures on revenue growth, profitability, customer churn, and independent validation of market coverage claims. This announcement is worth monitoring, as it signals real product traction, but it is not a sufficient basis for a major investment decision without more complete financial and competitive context. The single most important takeaway is that while Waystar’s operational impact is real for current users, the company’s broader market and financial claims remain only partially substantiated—investors should demand more transparency before committing significant capital.

Announcement summary

(NASDAQ:WAY) Waystar, a provider of healthcare payment software, released The State of the Mid-Revenue Cycle report, highlighting the impact of its AI-powered platform. The spring 2026 market survey of 50 healthcare finance, revenue cycle, and mid-cycle leaders found that 86% lack true integration between mid-cycle and final claim systems, and 82% cannot keep pace with rapidly changing payer clinical policies. Organizations fully leveraging Waystar's integrated clinical documentation integrity (CDI) workflows achieve an 87% increase in CDI program impact, generate $2.17 million in incremental reimbursement per 10,000 discharges, and improve Patient Safety Indicator Composite (PSI-90) scores by an average of 8.4 points. Providers using Waystar's advanced utilization management workflows increase observation-to-inpatient conversion rates by 13% and reduce medical-necessity denial rates to less than 2%. Organizations utilizing Waystar's automated charge, coding, and documentation reviews can unlock up to $3 million in incremental revenue per 10,000 admissions, with net rebilled dollars for coding anomalies increasing by 90% per 10,000 discharges compared with 2024 results. Waystar's platform annually processes over 7.5 billion healthcare payment transactions, including over $2.4 trillion in annual gross claims, and serves over 30,000 clients representing over 1 million distinct providers. The company projects that improving mid-cycle performance requires a unified, end-to-end, AI-powered platform and outlines five actionable strategies to improve visibility, prevent revenue leakage earlier, and deliver stronger ROI.

Disagree with this article?